Tesorai raises $5.3 million to reprocess life sciences data
Tesorai raised $5.3 million in seed funding, bringing total backing to $8 million as its AI platform reprocesses raw life sciences data for faster research.
By Nathan Brooks
4 min read

What's News
- $5.3 million seed round brings Tesorai’s total funding to $8 million.
- Eight investors joined the round, including Perplexity Fund, IQT and South Central Ventures.
- Tesorai says its patented model processes thousands of files and terabytes in hours, versus months in conventional workflows.
- A five-study brain-data demonstration recovered p-tau217, an Alzheimer’s marker the original studies had not reported.
- Protein data enabled a relatively small single-cell AI model to match or outperform larger RNA-only models across several benchmarks.
By Nathan Brooks
Tesorai raised $5.3 million in seed financing, bringing the company’s total funding to $8 million. Tesorai said the capital will expand an AI platform that processes and harmonizes raw experimental data for life sciences research.
Tesorai listed eight investors in the seed round:
- Perplexity Fund
- IQT
- South Central Ventures
- New Stack Ventures
- NextGen Venture Partners
- f7 Ventures
- VitalStage Ventures
- ZAKA
Tesorai said the financing will support three areas of expansion. The company plans to deepen its work with biopharmaceutical companies and research organizations, develop partnerships across the life sciences tools sector, and extend the platform into additional types of molecular data.
What changes for research teams?
Tesorai says laboratories can recover more value from experimental files already held in public repositories, corporate databases and institutional archives. The company said those files often carry inconsistent formats, so its platform returns to the underlying raw data and reprocesses it to make results from separate studies searchable and comparable.
Tesorai’s cloud platform has three named products:
- Tesorai Search processes raw experimental files in the cloud.
- Tesorai Chat lets scientists conduct downstream analyses through conversational prompts.
- Tesorai Trove lets researchers compare findings with thousands of earlier studies.
The company said its patented model can process thousands of files and terabytes of data in hours. Tesorai contrasted that performance with the months sometimes required by conventional workflows.
In one demonstration, Tesorai reprocessed raw files from five public brain studies. The company said it recovered p-tau217, a major Alzheimer’s disease marker that the original studies had not reported.
Tesorai’s researchers also reported that adding protein data enabled a relatively small single-cell AI model to match or outperform larger models trained solely on RNA data. The company said the result held across several benchmarks.
Tesorai has signed contracts with biopharmaceutical and research organizations. The company has also collaborated with MD Anderson Cancer Center, New York University and the Michael J. Fox Foundation.
The company was founded by former Google and Verily executives Melissa Miao, Peter Cimermancic and Charlie Kim. Miao serves as Co-Founder and CEO, Cimermancic as Co-Founder and Chief Technology Officer, and Kim as Co-Founder and Chief Scientific Officer.
The case for reusing experiments
Melissa Miao, Co-Founder and CEO of Tesorai:
“Every experiment produces far more data than its paper can report, and most of it is never revisited. Our platform reclaims the value of experiments that have already been done and amplifies each new experiment with the relevant evidence that already exists.”
Charlie Kim, Co-Founder and Chief Scientific Officer of Tesorai:
“Life science R&D is accelerating and becoming increasingly autonomous, which makes it more important to extract as much insight as possible from every experiment.
Tesorai does this for a lab’s new data and for thousands of published studies. The gains compound as each experiment builds on the last, and ultimately, this helps the industry develop better medicines and products, faster.”
Peter Cimermancic, Co-Founder and Chief Technology Officer of Tesorai:
“The quality of data and metadata a model learns from can matter as much as the size of the dataset, and much of the data that biology’s AI models need has already been collected. Yet only a small fraction of it is readily accessible, harmonized, and usable today.”
Investors bet on usable data
Joanna Lee Shevelenko, Co-Founder and General Partner of Perplexity Fund:
“AI has the potential to dramatically accelerate scientific research, but its impact will depend on access to high-quality experimental data. Tesorai is building the infrastructure to make that data usable at scale, giving scientists and AI systems a stronger foundation for advancing research.”
Tatjana Zabasu Mikuž, Managing Partner at South Central Ventures:
“Labs are generating more experimental data than ever, but its full value depends on processing that data efficiently. Tesorai’s team has built AI that does that at scale, for the experiments labs run today and the thousands already sitting in public archives.”
Tesorai’s signed contracts, planned tools-sector partnerships and broader molecular coverage will test whether the speed shown in its five-study demonstration scales. The $5.3 million seed now shifts the company’s challenge from proving throughput to proving repeatable research outcomes across larger deployments.
Source: pulse2.com
More from Nathan Brooks
Show full bio
News editor covering regulation, policy and their impact on entrepreneurship, startups and venture funding at Business Bearings.
2,473 articles